Ciraparantag-d₈ tetrahydrochloride diacetate  (Synonyms: PER977-d₈ tetrahydrochloride diacetate)

Ciraparantag-d8 tetrahydrochloride diacetate (PER977-d8 tetrahydrochloride diacetate) is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban^[1][2][3][4].

786.69

C₂₆H₅₂D₈Cl₄N₁₂O₆

1438492-26-2

O=C(NCCCN1C([2H])([2H])C([2H])([2H])N(CCCNC([C@@H](N)CCCNC(N)=N)=O)C([2H])([2H])C1([2H])[2H])[C@@H](N)CCCNC(N)=N.CC(O)=O.CC(O)=O.Cl.Cl.Cl.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25.  [Content Brief]

  [2]. Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10.  [Content Brief]

  [3]. Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44.  [Content Brief]

  [4]. Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48(2):144-158.  [Content Brief]